U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 1077

1.
A comprehensive single-cell RNA transcriptomic analysis identifies a unique SPP1+ macrophages subgroup in aging skeletal muscle
Wen Bi, Mengyue Yang, Mengjia Shi, Mirong Hou, Changqing Jiang, Gang Fan, Weiming Guo
Sci Rep. 2024; 14: 18156. Published online 2024 Aug 6. doi: 10.1038/s41598-024-69284-9
PMCID:
PMC11300837
AbstractArticlePDF–12M
2.
Nanoformulation of dasatinib cannot overcome therapy resistance of pancreatic cancer cells with low LYN kinase expression
Marilyn Kaul, Ahmed Y. Sanin, Wenjie Shi, Christoph Janiak, Ulf D. Kahlert
Pharmacol Rep. 2024; 76(4): 793–806. Published online 2024 May 13. doi: 10.1007/s43440-024-00600-w
PMCID:
PMC11294441
AbstractArticlePDF–3.3M
3.
Senolytic Treatment Improve Small Intestine Regeneration in Aging
Qing-Tian Luo, Yuan-Chun Ye, Wei-Ming Guo, Qing Zhu, Sa-Shuang Wang, Nan Li, Lei Wang, Chun-Sheng Cheng, Gang Fan
Aging Dis. 2024 Aug 1; 15(4): 1499–1507. Published online 2024 Aug 1. doi: 10.14336/AD.2023.0920
PMCID:
PMC11272202
AbstractArticlePDF–848K
4.
A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions
Christina Kovar, Helena Leonie Hanae Loer, Simeon Rüdesheim, Laura Maria Fuhr, Fatima Zahra Marok, Dominik Selzer, Matthias Schwab, Thorsten Lehr
CPT Pharmacometrics Syst Pharmacol. 2024 Jul; 13(7): 1144–1159. Published online 2024 May 1. doi: 10.1002/psp4.13146
PMCID:
PMC11247110
AbstractArticlePDF–1.8M
5.
SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma
Iris S. Luk, Caroline M. Bridgwater, Angela Yu, Liberalis D. Boila, Mariana Yáñez-Bartolomé, Aaron E. Lampano, Taylor S. Hulahan, Myriam Boukhali, Meena Kathiresan, Teresa Macarulla, Heidi L. Kenerson, Naomi Yamamoto, David Sokolov, Ian A. Engstrom, Lucas B. Sullivan, Paul D. Lampe, Jonathan A. Cooper, Raymond S. Yeung, Tian V. Tian, Wilhelm Haas, Supriya K. Saha, Sita Kugel
Sci Transl Med. Author manuscript; available in PMC 2024 Jul 2.
Published in final edited form as: Sci Transl Med. 2024 May 15; 16(747): eadj7685. Published online 2024 May 15. doi: 10.1126/scitranslmed.adj7685
PMCID:
PMC11218711
AbstractArticlePDF–3.0M
6.
Dasatinib promotes muscle differentiation and disrupts normal muscle regeneration
Nanami Ishida, Tamaki Kurosawa, Momo Goto, Noriyuki Kaji, Yayoi Tokunaga, Taiki Mihara, Masatoshi Hori
Int J Med Sci. 2024; 21(8): 1461–1471. Published online 2024 May 27. doi: 10.7150/ijms.94938
PMCID:
PMC11186431
AbstractArticlePDF–8.3M
7.
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL
Gaia Gentile, Teresa Poggio, Antonella Catalano, Minna Voutilainen, Mari Lahnalampi, Marta Andrade-Martinez, Tobias Ma, Roman Sankowski, Lina Goncharenko, Stefan Tholen, Kyuho Han, David W. Morgens, Marco Prinz, Michael Lübbert, Sophia Engel, Tanja Nicole Hartmann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Stanulla, Justus Duyster, Peter Bronsert, Michael C. Bassik, Michael L. Cleary, Oliver Schilling, Merja Heinäniemi, Jesús Duque-Afonso
Blood Adv. 2024 Jun 11; 8(11): 2846–2860. Published online 2024 Apr 12. doi: 10.1182/bloodadvances.2023011582
PMCID:
PMC11176965
AbstractArticlePDF–3.8M
8.
Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2
Sara Ahmed Eltayeb, Julia M. Dressler, Lukas Schlatt, Moritz Pernecker, Ute Neugebauer, Uwe Karst, Giuliano Ciarimboli
Arch Toxicol. 2024; 98(7): 2131–2142. Published online 2024 Apr 8. doi: 10.1007/s00204-024-03742-1
PMCID:
PMC11169033
AbstractArticlePDF–971K
9.
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling
Carlos Marugán, Natalia Sanz‐Gómez, Beatriz Ortigosa, Ana Monfort‐Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno‐Bueno, Guillermo de Cárcer
Mol Oncol. 2024 Jun; 18(6): 1531–1551. Published online 2024 Feb 15. doi: 10.1002/1878-0261.13602
PMCID:
PMC11161735
AbstractArticlePDF–8.6M
10.
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification
Takeshi Yoshida, Isamu Okamoto, Wataru Okamoto, Erina Hatashita, Yuki Yamada, Kiyoko Kuwata, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa
Cancer Sci. 2010 Jan; 101(1): 167–172. Published online 2009 Sep 14. doi: 10.1111/j.1349-7006.2009.01368.x
PMCID:
PMC11158912
AbstractArticlePDF–505K
11.
Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy
Théo Ribierre, Alexandre Bacq, Florian Donneger, Marion Doladilhe, Marina Maletic, Delphine Roussel, Isabelle Le Roux, Francine Chassoux, Bertrand Devaux, Homa Adle-Biassette, Sarah Ferrand-Sorbets, Georg Dorfmüller, Mathilde Chipaux, Sara Baldassari, Jean-Christophe Poncer, Stéphanie Baulac
Nat Neurosci. 2024; 27(6): 1125–1136. Published online 2024 May 6. doi: 10.1038/s41593-024-01634-2
PMCID:
PMC11156583
AbstractArticlePDF–10M
12.
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain
Inge van Outersterp, Sarah K. Tasian, Caitlin E. J. Reichert, Aurélie Boeree, Hester A. de Groot-Kruseman, Gabriele Escherich, Judith M. Boer, Monique L. den Boer
Blood. 2024 May 23; 143(21): 2178–2189. Published online 2024 Feb 26. doi: 10.1182/blood.2023023120
PMCID:
PMC11143520
AbstractArticle
13.
Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma
Guang-Tao Yu, Liang Mao, Lei Wu, Wei-Wei Deng, Lin-Lin Bu, Jian-Feng Liu, Lei Chen, Lei-Lei Yang, Hao Wu, Wen-Feng Zhang, Zhi-Jun Sun
Cell Mol Life Sci. 2018 Nov; 75(22): 4223–4234. Published online 2018 Jun 28. doi: 10.1007/s00018-018-2863-3
PMCID:
PMC11105240
AbstractArticlePDF–11M
14.
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Akriti G Jain, Quinto Gesiotto, Somedeb Ball, Lisa Nodzon, Amanda Rodriguez, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David A. Sallman, Jeffrey E Lancet, Javier Pinilla-Ibarz, Kendra Sweet
Ann Hematol. 2024; 103(6): 1941–1945. Published online 2024 Apr 18. doi: 10.1007/s00277-024-05760-6
PMCID:
PMC11090947
AbstractArticlePDF–662K
15.
Cellular senescence of granulosa cells in the pathogenesis of polycystic ovary syndrome
Tsurugi Tanaka, Yoko Urata, Miyuki Harada, Chisato Kunitomi, Akari Kusamoto, Hiroshi Koike, Zixin Xu, Nanoka Sakaguchi, Chihiro Tsuchida, Airi Komura, Ayaka Teshima, Nozomi Takahashi, Osamu Wada-Hiraike, Yasushi Hirota, Yutaka Osuga
Mol Hum Reprod. 2024 May; 30(5): gaae015. Published online 2024 Apr 11. doi: 10.1093/molehr/gaae015
PMCID:
PMC11060870
AbstractArticlePDF–2.5M
16.
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib
Annkristin Heine, Judith Schilling, Barbara Grünwald, Achim Krüger, Heidrun Gevensleben, Stefanie Andrea Erika Held, Natalio Garbi, Christian Kurts, Peter Brossart, Percy Knolle, Linda Diehl, Bastian Höchst
Cancer Immunol Immunother. 2016 Mar; 65(3): 273–282. Published online 2016 Jan 19. doi: 10.1007/s00262-015-1790-5
PMCID:
PMC11029563
AbstractArticlePDF–3.0M
17.
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors
Mark-Alexander Schwarzbich, Michael Gutknecht, Julia Salih, Helmut R. Salih, Peter Brossart, Susanne M. Rittig, Frank Grünebach
Cancer Immunol Immunother. 2012 Feb; 61(2): 193–202. Published online 2011 Aug 27. doi: 10.1007/s00262-011-1096-1
PMCID:
PMC11028554
AbstractArticlePDF–589K
18.
Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication
Min Young Lee, Chan-Jeoung Park, Young-Uk Cho, Eunkyoung You, Seongsoo Jang, Chang Ahn Seol, Eul-Ju Seo, Eun-Ji Choi, Je-Hwan Lee
Cancer Immunol Immunother. 2020 Nov; 69(11): 2223–2232. Published online 2020 May 30. doi: 10.1007/s00262-020-02617-5
PMCID:
PMC11027680
AbstractArticlePDF–1.2M
19.
Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19
Kun-Han Hsieh, Chiao-Hsuan Chao, Yi-Ling Cheng, Yen-Chung Lai, Yung-Chun Chuang, Jen-Ren Wang, Sui-Yuan Chang, Yuan-Pin Hung, Yi-Ming Arthur Chen, Wei-Lun Liu, Woei-Jer Chuang, Trai-Ming Yeh
J Biomed Sci. 2024; 31: 39. Published online 2024 Apr 18. doi: 10.1186/s12929-024-01026-5
PMCID:
PMC11027296
AbstractArticlePDF–2.4M
20.
The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs
Daria A. Bogdanova, Ekaterina D. Kolosova, Tamara V. Pukhalskaia, Ksenia A. Levchuk, Oleg N. Demidov, Ekaterina V. Belotserkovskaya
Int J Mol Sci. 2024 Apr; 25(7): 4031. Published online 2024 Apr 4. doi: 10.3390/ijms25074031
PMCID:
PMC11012227
AbstractArticlePDF–1.8M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center